Recent progress in radioimmunotherapy for cancer

Area of Science:

• Oncology
• Radiotherapy
• Immunology

Background:

• Radioimmunotherapy (RAIT) enables targeted radiation delivery to diseased tissues, minimizing damage to healthy organs.
• Significant advancements have been made in applying RAIT to various human cancers, with notable success in hematologic malignancies.

Purpose of the Study:

• To review the progress and challenges of radioimmunotherapy in treating human malignancies.
• To highlight the efficacy of RAIT in hematologic cancers and explore its potential in solid tumors.

Main Methods:

• Systemic and locoregional administration routes of radioimmunotherapy were considered.
• The study reviewed clinical outcomes, particularly complete remission rates and dose-limiting toxicities.

Main Results:

• RAIT has achieved substantial complete remission rates in chemotherapy-resistant B-cell lymphomas, with nonmyeloablative regimens showing promise for initial therapy.
• While solid tumors are less responsive, locoregional administration, especially for small tumor burdens, yields encouraging results by improving tumor-to-normal tissue ratios.
• Bone marrow suppression is the primary dose-limiting toxicity across different administration routes.

Conclusions:

• Radioimmunotherapy is a highly effective treatment for hematologic malignancies and shows potential for solid tumors with optimized administration.
• Future research focusing on novel targeting molecules, chelation chemistry, and isotope utilization will expand RAIT applications.
• Integrating RAIT with other therapies and tailoring administration methods to specific cancers are key to enhancing its therapeutic potential.